Supplement: Omeprazole / Lansoprazole / Ranitidine in Infants

Choosing a suitable formulation of omeprazole / lansoprazole / ranitidine for infants can be problematic. Clinical practice does not always reflect the licensed products available. The purpose of this newsletter supplement is to assist clinicians and pharmacists in selection and administration of suitable products.

Last year, unlicensed ‘specials’ of omeprazole, lansoprazole and ranitidine cost the NHS in Northern Ireland over £1,000,000.

While a suspension may be needed in some patients, it is often not the best option.

Guidance on managing reflux in infants
If clinically indicated, a 4 week time-limited trial of a H2-receptor antagonist or a proton pump inhibitor (PPI) may be considered. Please refer to Northern Ireland Infant feeding guideline on the NI Formulary website for full details on managing reflux.

Choice of PPI — lansoprazole or omeprazole?
Royal Belfast Hospital for Sick Children (RBHSC) and the Royal Jubilee Maternity Service (RJMS) neonatal unit are moving to use lansoprazole orodispersible tablets as their preferred option. This is preferred over omeprazole suspension for a number of reasons, including bioavailability issues with omeprazole suspension, problems with enteral feeding tube blockage with omeprazole, and cost.

‘Off-label’ use or unlicensed ‘special’?
The General Medical Council advises that licensed medicines and indications should be used where possible. If this is not an option, consider using a licensed medicine in an unlicensed manner (‘off-label’ use). ‘Specials’ are unlicensed medicines and are not required to meet the same standards as licensed preparations. Prescribers assume greater liability when using them and they are considerably more expensive than licensed medicines. Practice-generated scripts for omeprazole or lansoprazole suspension will result in an unlicensed product being dispensed to the patient. Refer to ‘specials’ supplement on NI Formulary website for further information on ‘specials’.

The role of the community pharmacist
If omeprazole or lansoprazole suspension is prescribed, it has to be ordered as an unlicensed ‘special’, and costs can vary greatly. Community pharmacists are asked to inform the prescriber of the cost of omeprazole or lansoprazole suspension compared to orodispersible tablets before placing an order with a special order company. If the suspension continues to be prescribed, please consider checking alternative suppliers for cost-effective prices.

A need for review
As with any medicine, it is important to review the continued need for H2-receptor antagonist or PPI use. Risks associated with long-term use of PPIs have been reported. See Medicines Management Newsletter article August 2015 on NI Formulary website.
If there is need for continued use, i.e. the child continues to be symptomatic, ensure that the dose is still suitable for the child’s weight, i.e. dose escalation of the H2-receptor antagonist or PPI may be required as the child gains weight.

Healthcare professionals should explore all alternatives before deciding to prescribe a ‘special’
**Paediatric license:** Omeprazole is licensed for use in children from 1 year and > 10kg for the treatment of reflux oesophagitis, symptomatic treatment of heartburn and acid regurgitation in gastroesophageal reflux disease. In clinical practice, omeprazole is also used off license in children under 1 year.

**Preparations:** 10mg and 20mg tablets (MUPS®), 10mg and 20mg capsules, 10mg/5mL suspension (manufactured extemporaneously or ordered as a ‘special’).

---

### Omeprazole Dosage

<table>
<thead>
<tr>
<th>Age/weight</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neonate</td>
<td>700 micrograms/kg once daily (max. 2.8mg/kg)</td>
</tr>
<tr>
<td>1mth to 2yr</td>
<td>700 micrograms/kg once daily (up to 3mg/kg; max.20mg)</td>
</tr>
<tr>
<td>10 to 20kg</td>
<td>10mg once daily (max.20mg)</td>
</tr>
<tr>
<td>Child &gt;20kg</td>
<td>20mg once daily (max.40mg)</td>
</tr>
</tbody>
</table>

It is important that calculated doses are then considered in practical terms, in relation to available products, i.e. round to the nearest 5mg. In practice, children with a weight of ≥ 3.4kg may be given a dose of 10mg daily. A 5mg dose is usually only prescribed in the hospital setting for babies of low weight.

---

### Omeprazole Unlicensed ‘Specials’

- There is only limited evidence of efficacy for the omeprazole suspension. Orodispersible tablets should be used where possible.
- The sodium bicarbonate in the suspension gives it an unpleasant taste and a high sodium content.
- The suspension is usually reserved for children with feeding tubes under 12Fr in size.
- Omeprazole suspension can be ordered as an unlicensed preparation from special order companies. They are often formulated in the same way as the extemporaneous formulation, i.e. using omeprazole capsules in sodium bicarbonate.
- The price of omeprazole suspension can vary greatly between special order companies: invoices to BSO range from £23 to £1664 for omeprazole 10mg/5ml oral suspension.
- Please ensure a cost-effective product is ordered.

---

### Oral administration of Losec MUPS® tablets

**Children <1 year who are not spoon fed:**

- Use an oral syringe to administer the tablet.
- If a dose of 5mg is required, halve the tablet (using a tablet cutter) before dispersing.
- Place the tablet (or half of a tablet) in the barrel of an oral syringe.
- Replace the plunger and draw up 10mL of water. The resulting dispersion will contain enteric coated pellets.
- Give the 10mL dispersion to the infant.

If a 10mL oral syringe is not available, a medicine cup or 5mL oral syringe may be used to disperse the tablet in water. However, it is important to ensure that ALL of the pellets are drawn up into the oral syringe and administered.

**Note:** pellets tend to settle to the bottom in oral syringes / medicine cups and there is a risk that the child may not receive the full dose: ensure that all of the pellets are drawn up and administered.

**Aliquot:** are not suitable for administering doses under 10mg, i.e. do not try to dissolve a 10mg tablet in 10mL of water and assume 5mL will equal 5mg, as the pellets do not dissolve.

**Children who are spoon fed:**

Disperse the tablet (or half tablet, depending on dose) in a spoonful of non-carbonated water. If so wished, the dispersion may then be mixed with fruit juice or apple sauce. Always stir just before drinking and rinse down with half a glass of water. Do not use milk or carbonated water. Do not chew the enteric-coated pellets.

---

### Omeprazole 10mg/5mL suspension Extemporaneous Formulation

**Ingredients:**

- Omeprazole capsules 20mg x 28
- Sodium bicarbonate 8.4% x 280mL

**Method:** Open the omeprazole capsules and place contents in a mortar. Crush the granules and mix with a little sodium bicarbonate 8.4%. Make up to volume with the remainder of the sodium bicarbonate solution. Transfer to an amber bottle with an adaptor, label appropriately, and supply with an oral syringe.

**COSHH requirements:** wear gloves

**Expiry:** 28 days in fridge (2 to 8°C)
**LANSOPRAZOLE**

**Paediatric license:** Lansoprazole is not licensed in children due to limited clinical data. However there is increasing clinical experience and the Children’s BNF provides information on use of lansoprazole in infants.

**Preparations:** 15mg and 30mg Fastabs®, 15mg and 30mg capsules, oral suspension of various strengths (manufactured extemporaneously or ordered as a ‘special’).

<table>
<thead>
<tr>
<th>Lansoprazole Dosage</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Body weight</strong></td>
<td><strong>Dose</strong></td>
<td><strong>Preparation</strong></td>
</tr>
<tr>
<td>For infants under 2.5kg, there is less clinical experience with lansoprazole, therefore use omeprazole</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.5 to 5kg</td>
<td>3.75mg once daily</td>
<td>Quarter a 15mg tablet</td>
</tr>
<tr>
<td>5 to 10kg</td>
<td>7.5mg once daily</td>
<td>Half a 15mg tablet</td>
</tr>
<tr>
<td>10 to 30kg</td>
<td>15mg once daily</td>
<td>One 15mg tablet</td>
</tr>
<tr>
<td>&gt; 30kg</td>
<td>30mg once daily</td>
<td>One 30mg tablet</td>
</tr>
</tbody>
</table>

**Lansoprazole Unlicensed ‘Specials’**
- There is limited evidence of efficacy for the lansoprazole suspension. Therefore, orodispersible tablets should be used where possible.
- The sodium bicarbonate in the suspension gives it an unpleasant taste and a high sodium content.
- The suspension is usually reserved for children with feeding tubes under 12Fr in size.
- The price of lansoprazole suspension can vary greatly between special order companies. Please ensure a cost-effective product is ordered.

**Lansoprazole oral suspension Extemporaneous Formulation**
An oral suspension has been made with sodium bicarbonate, but is not as stable as omeprazole in sodium bicarbonate.

**RANITIDINE**

**Paediatric license:** Ranitidine is not licensed in children below 3 years of age. However there is experience with the use of ranitidine in infants, and the Children’s BNF provides information on doses of ranitidine in infants.

**Preparations:** 150mg/10mL oral solution, 75mg, 150mg and 300mg tablets, 150mg and 300mg effervescent tablets, oral suspension of various strengths (manufactured extemporaneously or ordered as a ‘special’).

<table>
<thead>
<tr>
<th>Ranitidine Dosage</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td><strong>Dose</strong></td>
<td></td>
</tr>
<tr>
<td>Neonate</td>
<td>2mg/kg three times daily</td>
<td></td>
</tr>
<tr>
<td>1 to 6mths</td>
<td>1mg/kg three times daily</td>
<td></td>
</tr>
<tr>
<td>6mths to 3yrs</td>
<td>2 to 4mg/kg twice daily</td>
<td></td>
</tr>
</tbody>
</table>

**Oral administration**
- The licensed 150mg/10mL liquid should be prescribed with a 1mL syringe to administer small doses to children, e.g. a dose of 4.3mg equates to 0.29mL. See page 4.
- Note: expiry of ranitidine liquid once opened.

**Enteral Feeding administration**
Although not licensed for enteral administration, the liquid preparation can be used for gastric administration (but note sorbitol content).
This newsletter has been produced for GP practice staff and pharmacists by the Regional Pharmacy and Medicines Management Team. If you have any queries or require further information on the contents of this newsletter, please contact one of the Pharmacy Advisors in your local HSCB office:

Belfast Office: 028 9536 3926  
South Eastern Office: 028 9147 5133

Southern Office: 028 9536 2009  
Northern Office: 028 9536 2845

Western Office: 028 9536 1008

Every effort has been made to ensure that the information included in this newsletter is correct at the time of publication. This newsletter is not to be used for commercial purposes.

References

1. NICE. NICE NG1 Gastro-oesophageal reflux disease in children and young people: diagnosis and management. 2015
2. Personal Communication, RBHSC and NHSCT.
4. EMC. Losec 10mg capsules SPC, last updated 30/9/2016 http://www.medicines.org.uk
5. EMC. Losec MUPS 10mg tablets SPC, last updated 5/10/2016 http://www.medicines.org.uk
11. EMC. Zoton FasTab SPC, last updated 12/4/2016 http://www.medicines.org.uk
12. EMC. Ranitidine Rosemont 150mg/10mL Oral Solution SPC, last updated 27/10/2015 http://www.medicines.org.uk